With the reflection of pathological patterns, the approved ongoing treatment approaches for AD treatment are acetylcholinesterase inhibitors (AChEIs) (donepezil, galanthamine and rivastigmine, all raising acetylcholine levels) and uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine, which normalizes dysfunctional glutamatergic neurotransmission [33]. The gene discussed is ACHE; the disease is Alzheimer disease.